Oncologic specimen from laparoscopic assisted gastrectomy for gastric adenocarcinoma is comparable to D1-open surgery: the experience of a Canadian centre

Julie Hallet, MD
Saber Labidi, MD
Antoine Bouchard-Fortier, MD
Ariane Clairoux, MD
Jean-Pierre Gagné, MD, LLM
From the Department of Surgery, Centre Hospitalier Universitaire de Québec, Québec Centre for Minimally Invasive Surgery, Québec, Que.

Accepted for publication
May 10, 2012


Correspondence to:
J.-P. Gagné
CHUQ
10, rue de l’Espinay
Québec QC G1L 3L5
jpgagnemjacques@gmail.com

DOI: 10.1503/cjs.002612

Background: The Eastern experience has reported the safety of laparoscopic assisted gastrectomy (LAG) for gastric cancer. Its use in Western countries is still debated owing to concerns about its oncologic equivalence to open gastrectomy (OG). We sought to review and compare their operative outcomes and oncologic specimen quality (number of harvested lymph nodes and surgical margins) for gastric adenocarcinoma (GA).

Methods: We reviewed the charts of all patients undergoing LAG (2007–2010) and OG (2000–2010) for GA in a single institution. Several surgeons performed the OGs, whereas 1 fellowship-trained laparoscopic surgeon performed LAGs. The primary outcome was quality of the surgical specimen, assessed by the number of harvested lymph nodes (LNs) and margin status. Secondary outcomes were perioperative events. Data were analyzed as intention to treat.

Results: We retrieved 60 cases (47 OGs, 13 LAGs). The conversion rate was 23%. Mean operative time was 115 minutes longer and blood loss was 425 mL less (both \( p < 0.001 \)) for LAGs. A mean of 14.4 (standard deviation [SD] 9.8) and 11.2 (SD 8.2) LNs were harvested for OGs and LAGs, respectively (\( p = 0.29 \)). Negative margins were achieved for all patients. Mean length of stay was similar (LAG: 19 d v. OG: 18.9 d; \( p = 0.91 \)). The groups did not differ on major postoperative complications (12.7% v. 23.1%; \( p = 0.39 \)) or operative mortality (2.1% v. 7.7%; \( p = 0.32 \)).

Conclusion: Laparoscopic assisted gastrectomy is a challenging but safe and feasible procedure in experienced hands. It offers the same radical resection as OG regarding negative margins and LN retrieval. Long-term follow-up is warranted.

Contexte : La gastrectomie assistée par laparoscopie (GAL) a été démontrée dans des études orientales comme sécuritaire dans le traitement de l’adénocarcinome gastrique (AG). En occident, l’équivalence oncologique de la GAL avec la gastrectomie ouverte (GO) demeure cependant controversée. Cette étude vise à comparer le devenir post-opératoire et la qualité des spécimens oncologiques de ces interventions, dans le traitement de l’AG.


Résultats : Soixante cas ont été inclus (47 GO, 13 GAL). Le taux de conversion s’est établi à 23 %. Le temps opératoire moyen était plus long de 115 minutes, et les pertes sanguines moyennement moindres de 425 mL (\( p < 0.001 \)) pour la GAL que pour la GO. Une moyenne de 14,4 (écart-type [ET] 9,8) et 11,2 (ET 8,2) GL ont été prélevés respectivement pour la GO et la GAL (\( p = 0.29 \)). On a obtenu des marges négatives pour tous les patients. La durée moyenne du séjour ne différait pas (GAL 19 j c. GO 18,9 j; \( p = 0.91 \)). Les complications majeures (12,7 % c. 23,1 %; \( p = 0.39 \)) et la mortalité post-opératoires (2,1 % c. 7,7 %; \( p = 0.32 \)) étaient similaires.

Conclusion : La gastrectomie assistée par laparoscopie est une intervention complexe, mais peut être réalisée de manière sécuritaire en des mains expertes. Elle offre un spécimen oncologique comparable à la gastrectomie ouverte, en termes de lymphadénectomie et de marges de résection. Un suivi à long terme demeure nécessaire.
S
ince Dubois and colleagues\(^1\) reported the first ex-
perience with laparoscopic cholecystectomy, begin-
ning in 1988, laparoscopic surgery has rapidly
gained popularity. Many reports have highlighted the
benefits of the laparoscopic approach over the open one
for the treatment of a variety of abdominal conditions,
mainly owing to a decrease in pain, blood loss, length of
hospital stay and complications. However, its use for the
treatment of malignant conditions has been more slowly
accepted because of concerns about the possibility to
achieve an equivalent oncologic procedure.

The only possible curative treatment for gastric adeno-
carcinoma is surgical resection. The first laparoscopic gastric
resection was reported in 1993.\(^2\) Since then, minimally inva-
sive gastric surgery has gained general acceptance for benign
conditions\(^3-4\) and some malignant ones for which extended
resection or lymphadenectomy is not required.\(^5\) Its role in
the treatment of gastric adenocarcinoma is still debated. The
extensive Asian experience, where gastric cancer is diagnosed
at an early stage, has confirmed the adequacy of laparoscopic
resection with regards to postoperative outcomes, technical
feasibility of appropriate lymphadenectomy and oncologic
outcomes.\(^6-12\) In Western countries, where gastric cancer is
less prevalent and diagnosed at an advanced stage in 75% of
patients,\(^13\) laparoscopic gastrectomy has not yet been accept-
ed as a curative treatment. Therefore, conclusions regarding
the treatment in large Asian trials cannot be generalized to
Western patients. Western data comparing laparoscopic to
open gastrectomy are challenged by small sample sizes and
limited follow-up.\(^14-17\) To our knowledge, no study has com-
pared both techniques specifically for malignant disease in
the Canadian setting.

The aim of this study was to review and compare the
quality of the oncological specimens obtained by laparo-
scopic assisted gastrectomy (LAG) versus open gastrec-
tomy (OG) for gastric adenocarcinoma in a Canadian aca-
demic health centre. We hypothesized that the margin
status and the number of harvested lymph nodes (LNs)
obtained with LAG would be similar to that with OG.

**METHODS**

We conducted a retrospective cohort study to compare
LAG and OG.

**Selection of participants**

All gastric resections performed from January 2000 to
November 2010 in a single academic institution (Centre
Hospitalier Universitaire de Québec, Québec, Que.) were
identified through the hospital administrative database.
Laparoscopic assisted gastrectomy was introduced in
2007. Afterwards, both techniques were used, and the
choice of approach was left to the surgeon’s discretion. We
included all adult patients (age \(\geq 18\) yr) with confirmed
gastric adenocarcinoma of all anatomic localizations sub-
mitted to either LAG or OG with a curative intent. We
excluded patients treated for benign conditions or mali-
gnant diseases other than adenocarcinoma. Reviewers not
involved in the treatment process obtained clinical and
pathological data from the patients’ charts.

**Outcome measures and data collection**

The primary outcome was the oncological quality of the
resected gastric specimen, as assessed by the number of
harvested LNs and margin status. Secondary outcomes
included operative duration, blood loss, length of stay and
postoperative morbidity.

Demographic and diagnostic data included age, sex,
body mass index (BMI), comorbidities and the use of a
neoadjuvant or adjuvant treatment. Operative data includ-
ed operative duration; estimated blood loss; gastrointes-
tinal reconstruction; length of stay; conversion rates; and
major complications, including cardiac (acute coronary
syndrome, arrhythmia, congestive heart failure) and respi-
atory events (respiratory failure requiring reintubation),
pancreatic fistula, intra-abdominal abscess, anastomotic
leak and postoperative mortality (within 30 d). We review-
ed pathology reports for final pathologic diagnosis, tumour
size, number of retrieved LNs, distal and proximal margins
status and pathologic TNM staging. Analysis of the lesion
size, margins status and harvested LNs was performed only
for curative intent resection; these elements were not taken
into consideration during palliative surgery.

**Technical information**

Four surgeons performed the procedures; all of them per-
formed OG, whereas only 1 of them, a fellowship-trained
laparoscopic surgeon, performed all LAGs. All surgeries
were booked with a curative intent. If curative resection
was deemed impossible, palliative surgery was carried on
based on the surgeon’s perioperative decision.

Open gastrectomies were performed through a midline
laparotomy. The type of gastric resection performed was
determined based on the tumour location, its size and the
depth of invasion; it was performed in a standard fashion
with a D1 lymphadenectomy, including LN stations 1–6,
according to the Japanese Research Society for Gastric Cancer.\(^18\)

For LAGs, patients under general anesthesia were
placed in the supine split leg position with the surgeon
standing between the legs. A 5-trocar technique was used
to perform subtotal or total gastrectomy and D1 lymph-
adenectomy. Pneumoperitoneum at 15 mm Hg was estab-
lished through an open umbilical approach. After careful
exploration of the peritoneal cavity, gastric dissection
began with mobilization of the greater curvature. The
greater omentum was included in the specimen. Dissection
was then continued toward the spleen with division of the short gastric vessels using LigaSure (Covidien) and toward the pylorus to include infrapyloric LNs and divide the right gastroepiploic artery and vein at the level of the pancreatic border. The dissection continued on the lesser curvature; the lesser omentum was opened, and the right gastric artery was exposed and divided between metallic clips. Dissection then continued toward the gastrosophageal junction. The left gastric artery was exposed and divided at its root. All perigastric LNs were carefully dissected along the lesser curvature, the left gastric artery and the distal portion of the hepatic artery. The duodenum was then divided 3 cm distal to the pylorus, immediately above the gastroduodenal artery. Through a small 5 cm upper-midline incision protected by an Alexis retractor (Applied Medical), the proximal stomach was transected obliquely at a distance depending on the tumour location using multiple firings of a 3.5 mm Endo GIA stapler (Covidien). The resected specimen was then extracted, with the wound protected from tumour spillage by the Alexis retractor, and gastrointestinal reconstruction was completed. An anterior retrocolic Billroth II technique was used for subtotal gastrectomies. For total gastrectomies, Roux-en-Y was combined with the transoral anvil placement of a CEEA (Covidien) for the esophagojejunal anastomosis.

Pathologists specializing in gastrointestinal tumours analyzed all specimens. Tumours were classified according to the pathologic stage, following the guidelines of the *AJCC Cancer Staging Manual*, 6th edition. The number of LNs in the specimen was assessed by naked-eye dissection.

**Statistical analysis**

We performed our analyses using XLSTAT version 2010.6 (Addinsoft SARL) for Microsoft Excel. Continuous data are expressed as means with standard deviations (SD) or medians with interquartile ranges (IQR), as appropriate. Categorical data are reported as proportions. We compared OG and LAG groups using a 2-sample *t* test, Fisher exact test or Pearson *χ*² test, as appropriate. Missing data were estimated by the mean for quantitative variables and by the mode for categorical variables. We applied the intention-to-treat principle to the data analysis, with the data of patients converted from LAG to OG analyzed in the LAG group. We considered results to be significant at *p* < 0.05.

**RESULTS**

Seventy-four gastrectomies were performed in our institution during the study period (Fig. 1). Of these, 14 cases were excluded (8 gastrointestinal stromal tumour, 1 melanoma, 4 benign lesions, 1 incomplete chart rendering data collection impossible). Thus, 60 cases (13 LAGs and 47 OGs) were included in our analyses. Curative treatment was intended for 10 (76.9%) patients who underwent LAG and 36 (76.6%) who underwent OG; these patients were included in our analysis of the oncologic assessment of the specimens.

Demographic data and preoperative characteristics for all patients are presented in Table 1. The age, sex and BMI distribution did not differ between the groups. More patients in the LAG than the OG group had cardiovascular disease (30.7 v. 0%) and diabetes (30.7 v. 6.4%, *p* = 0.034). There was no difference in the use of neoadjuvant chemotherapy.

Operative characteristics and postoperative follow-up are summarized in Table 2. The median operative duration was 115 minutes longer for laparoscopic than the open cases (*p* < 0.001), and the median estimated blood loss was 423 mL greater in the open than the LAG group (*p* < 0.001). There were 3 (23.1%) conversions in the LAG group. The extent of resection was not statistically different between the groups. However, there was a trend toward fewer total gastrectomies in the LAG group (7.7% v. 36.2%). Billroth II reconstruction was used more often in the LAG than the OG group (92.3 v. 61.7%, *p* = 0.045).

We observed no difference in the median length of stay (10.0 d in the LAG v. 13.0 d in the OG group, *p* = 0.91). One postoperative death (<30 d) occurred in each group (*p* = 0.39). Overall there was no difference in postoperative
morbidity (23.1 in the LAG v. 12.7% in the OG group, \( p = 0.39 \)). However, 2 leaks (15.4%; 1 at the gastrojejunal anastomosis in the immediate postoperative period, 1 at the duodenal stump) occurred in the LAG group compared with none in the OG group. The median follow-up was different between the groups (286.5 d in the LAG v. 550 d in the OG group, \( p < 0.001 \)).

Oncologic assessment of the surgical specimen is presented in Table 3. More patients with stage II disease were treated with LAG than OG (38.5 v. 10.6%, \( p = 0.031 \)). Overall, 56.7% of patients presented with advanced gastric cancer (stage III or IV). The mean lesion size was 4.5 (SD 2.0) cm in the LAG group and 5.3 (SD 2.5) cm in the OG group (\( p = 0.12 \)). Negative margins were obtained for all cases with a curative intent. A mean of 11.2 (SD 8.2) LNs were collected in the LAG group compared with 14.4 (SD 9.8) in the OG group (\( p = 0.29 \)).

**DISCUSSION**

To our knowledge, this is the first report of a Canadian experience that compares LAG to OG for gastric adenocarcinoma exclusively. We chose to consider only adenocarcinoma because resections for other gastric lesions do not imply the same need for lymphadenectomy. The oncologic quality of the specimens did not differ between LAG and OG, with a similar number of negative margins and mean of harvested LNs for a D1 dissection. Estimated blood loss was lower in the LAG than the OG group.

---

**Table 1. Demographic and preoperative characteristics of patients undergoing gastrectomy**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Surgical approach, no. (%)</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, no.</td>
<td>OG  47</td>
<td>LAG  13</td>
</tr>
<tr>
<td>Age, mean (SD) yr</td>
<td>74.6 (8.1)</td>
<td>68.6 (12.4)</td>
</tr>
<tr>
<td>Sex, no. male:female</td>
<td>28:19</td>
<td>5:8</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>20.9 (9.7)</td>
<td>25.2 (4.9)</td>
</tr>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>24 (51.1)</td>
<td>4 (30.7)</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td>0 (0)</td>
<td>4 (30.7)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>3 (6.4)</td>
<td>4 (30.7)</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>7 (14.9)</td>
<td>4 (30.7)</td>
</tr>
<tr>
<td>Stage according to pTNM†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>13 (27.7)</td>
<td>3 (23.1)</td>
</tr>
<tr>
<td>II</td>
<td>5 (10.6)</td>
<td>5 (38.5)</td>
</tr>
<tr>
<td>III</td>
<td>21 (47.7)</td>
<td>3 (23.1)</td>
</tr>
<tr>
<td>IV</td>
<td>8 (17.0)</td>
<td>2 (15.4)</td>
</tr>
<tr>
<td>Neoadjuvant chemotherapy‡</td>
<td>1 (2.1)</td>
<td>2 (15.4)</td>
</tr>
</tbody>
</table>

BMI = body mass index; LAG = laparoscopic assisted gastrectomy; OG = open gastrectomy; pTNM = pathological tumour, node, metastasis; SD = standard deviation.

*Unless otherwise indicated.


‡MAGIC protocol.

---

**Table 2. Operative characteristics and postoperative follow-up of patients undergoing gastrectomy**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Surgical approach; no. (%)</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curative intent treatment</td>
<td>36 (76.6)</td>
<td>10 (76.9)</td>
</tr>
<tr>
<td>Operative time, median (IQR) min</td>
<td>192 (172.5–262.5)</td>
<td>307.5 (283.5–350.5)</td>
</tr>
<tr>
<td>EBL, median (SD) mL</td>
<td>550 (300–910)</td>
<td>125 (100–300)</td>
</tr>
<tr>
<td>Conversion to open</td>
<td>—</td>
<td>3 (23.1)</td>
</tr>
<tr>
<td>Procedure performed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total gastrectomy</td>
<td>17 (36.2)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Subtotal gastrectomy</td>
<td>27 (57.4)</td>
<td>9 (69.2)</td>
</tr>
<tr>
<td>Limited resection†</td>
<td>3 (6.4)</td>
<td>3 (23.1)</td>
</tr>
<tr>
<td>Gastrointestinal reconstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Billroth I</td>
<td>1 (2.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Billroth II</td>
<td>29 (61.7)</td>
<td>12 (92.3)</td>
</tr>
<tr>
<td>Roux-en-Y</td>
<td>17 (36.2)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Major postoperative morbidity</td>
<td>6 (12.7)</td>
<td>3 (23.1)</td>
</tr>
<tr>
<td>Cardiac</td>
<td>2 (4.3)</td>
<td>2 (15.4)</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>1 (2.1)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Intra-abdominal abscess</td>
<td>4 (2.1)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Pancreatic fistula</td>
<td>1 (2.1)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Anastomotic leak</td>
<td>0 (0)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Duodenal stump leak</td>
<td>0 (0)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>LOS, median (IQR) d</td>
<td>13.0 (10.5–23.0)</td>
<td>10.0 (7.0–22.7)</td>
</tr>
<tr>
<td>Postoperative mortality†</td>
<td>1 (2.1)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Follow-up, median (IQR) d</td>
<td>550 (248.5–1117.7)</td>
<td>286.5 (170.25–334.25)</td>
</tr>
</tbody>
</table>

EBL = estimated blood loss; IQR = interquartile range; LAG = laparoscopic assisted gastrectomy; OG = open gastrectomy; SD = standard deviation.

*Unless otherwise indicated.

†Antrectomy or wedge resection for palliative purpose.

‡< 30 postoperative days.
mean operative duration was longer for the laparoscopic approach, probably because of the technical challenge of LAG and the introduction phase of the technique. However, it did not translate to a difference in overall postoperative morbidity. Three conversions from LAG to OG were necessary: 2 for suspected invasion of the pancreatic head and 1 for a challenging distal pyloric margin. More total gastrectomies were performed in the OG than the LAG group, which may reflect the technical challenge associated with LAG. Two leaks occurred in the LAG group, whereas none was recorded after OG. The first leak was an early occurrence at the gastrojejunostomy and was attributed to technical failure. This obese patient had an antecolic Billroth II stapled reconstruction. Unfortunately, she fell in the immediate postoperative period and presented a bilious leakage from a trocar wound on postoperative day 1. Our impression is that the anastomosis was torn apart by the weight of the heavy unprepared transverse colon. The second leak was observed at the duodenal stump when resuming chemotherapy 6 weeks after surgery (MAGIC protocol). This patient was seen for routine follow-up at 3 weeks postoperatively and was then asymptomatic. Overall, the clinical characteristics of the groups were similar at baseline except for cardiovascular disease and diabetes, which disfavoured the LAG group. More early stage lesions (stage II) were treated with LAG than OG, which could reflect either a preference for a laparoscopic approach to treat earlier lesions or a tendency to diagnose gastric cancer earlier in the latter part of the study period, since LAG was performed starting in 2007.

As previously stated, the laparoscopic approach for gastric diseases is now accepted for benign lesions or malignant ones that do not require extensive lymphadenectomy. The technique is, however, more controversial for gastric adenocarcinoma. A large body of evidence comes from the Asian literature. Laparoscopic assisted gastrectomy was first used for early gastric cancer, for which lymphadenectomy is not as essential, and was shown to be as safe as OG in addition to providing postoperative benefits such as a shorter hospital stay, earlier mobilization, fewer pulmonary complications and an earlier functional recovery. Retrospective evidence followed for treatment of advanced gastric cancer, with studies reporting equivalent radical oncology resection and improved postoperative suites and recovery. However, the portrait of gastric cancer in Western countries differs. Prevalence is lower, and more advanced lesions are treated, with 75% being stage III to IV at diagnosis. Therefore, the Asian data cannot be readily applied to Western patients.

Few Western studies are available to address the many issues that have been raised regarding the technical and oncological safety of LAG. Comparative studies consisted of retrospective designs, case-matched cohorts and a single prospective randomized controlled trial (RCT) by Huscher and colleagues. Sample sizes were limited owing to the Western gastric cancer reality. Francescutti and colleagues have reported the only previous Canadian experience, but they included patients with benign lesions as well as those with malignant ones. All comparative studies have reported decreased or similar early postoperative morbidity with LAG ranging from 0% to 26%, which compares with our results. Other benefits of the laparoscopic approach, including decreased time to ambulation and resumed diet, decreased consumption of analgesia and a shorter length of stay, have been reported in these studies. However, we found no difference in length of stay. We performed a laparoscopic assisted technique that included a limited median incision for digestive reconstruction. This may have affected the length of stay. Since this is an early experience, postoperative management was probably more cautious and did not reflect a fast track philosophy. The information available in the chart did not allow us to capture sufficient, consistent details regarding analgesia usage or diet resumption to report them.

From an oncologic perspective, many are worried that LAG would not offer the same radical resection as OG. Issues regarding the pneumoperitoneum and peritoneal implants have already been addressed and refuted by studies on colorectal cancer. Fear remains that these results would not apply to the different biological behaviour of gastric cancer. In a large retrospective cohort study of 1417 patients treated with LAG for gastric cancer, Song and colleagues reported a 13.4% recurrence for advanced gastric cancer and observed a pattern and timing of recurrence similar to that described after open surgery. Another concern regards the feasibility of an adequate lymphadenectomy. Strong and colleagues reported a significantly decreased number of harvested LNs with LAG in a case-matched study of 60 patients (18 with LAG vs. 21 with OG, \( p = 0.03 \)). Others reported no difference between the laparoscopic and open approaches. In a meta-analysis of RCTs comparing laparoscopic and open approaches for early gastric cancer, Ohtani and colleagues concluded that there was a lesser number of LNs with laparoscopy. Debate is still ongoing about the extent of the lymphadenectomy and the number of LNs needed in the specimen. Gastrectomy with D2 dissection is the standard of care for curable gastric cancer in Asia. In Western countries, no survival

![Table 3: Pathologic characteristics after gastrectomy with curative intent](image)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Surgical approach</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumour size, mean (SD) cm</td>
<td>OG 5.2 (2.5)</td>
<td>4.5 (2.0)</td>
</tr>
<tr>
<td>R0 resection rate, no. (%)</td>
<td>36 (100)</td>
<td>10 (100)</td>
</tr>
<tr>
<td>No. of harvested LNs, mean (SD)</td>
<td>14.4 (9.8)</td>
<td>11.2 (8.2)</td>
</tr>
</tbody>
</table>

LAG = laparoscopic assisted gastrectomy; LN = lymph node; OG = open gastrectomy; SD = standard deviation.

Can J Surg, Vol. 56, No. 4, August 2013 253

RESEARCH
benefit has been revealed by 2 RCTs comparing D2 to D1 dissection.\textsuperscript{17,18} However, 15-year follow-up data from the Dutch trial\textsuperscript{19} have recently shown a significant decrease in gastric cancer–related death with D2 dissection.\textsuperscript{16} At this time, the current Western guidelines recommend including at least 15 LNs in the dissection to allow proper staging, without mentioning the level of LN dissection.\textsuperscript{40} We reported no difference in the number of LNs between groups, but neither achieved the 15 LNs required, despite a meticulous D1 surgical technique. The pathology team at our institution relies on standard manual LN dissection after formalin fixation. This approach is known to retrieve significantly fewer LNs in patients with colorectal cancer.\textsuperscript{41} Furthermore, our results are consistent with most published results of D1 dissection. Francescutti and colleagues\textsuperscript{27} retrieved a similar mean of 11.8 LNs in LAG compared with 7.3 in OG ($p=0.21$). Weber and colleagues\textsuperscript{1} obtained a mean of 8 and 11 LNs, respectively, when comparing LAG and OG. Overall, we were able to harvest a reasonable and comparable number of LNs with LAG and OG, considering the standard of care at the time of study. The level of LN dissection for gastric adenocarcinoma is a rapidly evolving topic. Considering the recent data, D2 dissection will probably become a standard of care, and laparoscopic D2 will need to be further developed. No margins were positive for patients treated with a curative intent, so no difference was observed between groups, which is consistent with the current Western literature.\textsuperscript{15,16,26–31,33} However, obtaining a safe distal margin laparoscopically can be challenging for lesions seating close to the pylorus. This was the reason for 1 of the conversions in the LAG group in our study.

Short follow-up and small sample size in the LAG group precluded proper recurrence or survival analysis in the present study. Huscher and colleagues,\textsuperscript{40} in the only Western prospective RCT, revealed no significant difference between LAG and OG in 5-year overall survival (58.9% v. 55.7%) and recurrence-free survival (57.3% v. 54.8%). This has also been observed in retrospective studies. Moisan and colleagues\textsuperscript{35} observed no difference in 3-year overall survival comparing LAG and OG (74% v. 75%, $p=0.88$) and 3-year disease-free survival (77.8% v. 68.8%, $p=0.90$). In a case-matched study from the Memorial Sloan Kettering Cancer Center, Strong and colleagues\textsuperscript{17} also found no difference in 3-year survival.

**Limitations**

Because of its retrospective design and the small sample size, our study has several limitations. A selection bias cannot be overlooked. All gastric cancers were treated with OG before 2007. Afterwards, both OG and LAG were used depending on the surgeon’s preference, which inevitably led to early stage tumours being approached laparoscopically. A historical bias can also be considered, since neoadjuvant chemotherapy protocols were introduced in 2006,\textsuperscript{42} but both groups were comparable on that aspect, and survival was not an outcome of interest. As all cases were booked with curative intent, we chose to include palliative surgeries in the perioperative outcomes analysis to reflect the clinical reality of the surgical treatment of gastric adenocarcinoma. Laparoscopic assisted gastrectomies were performed by a single surgeon, which limits the generalizability of our results. Laparoscopic gastric surgery remains a challenging technique with a steep learning curve. Solid laparoscopic experience is necessary to perform complex gastric procedures, such as lymphadenectomy for cancer. Considering the small number of cases of gastric cancers in Western countries and the growing complexity of their management, it is not expected that these results will need to be reproduced outside of expert centres. Also, at the moment, LAG appears more suited for early stage lesions, which represent the minority of cases in Western countries; this may further affect the widespread use of LAG.

**Conclusion**

This study reports the feasibility and surgical specimen equivalence of LAG compared with OG in a Canadian setting. This approach for gastric adenocarcinoma resection cannot be applied to every patient. Contraindications could include prior abdominal surgeries, prior radiotherapy in the surgical field, invasion of other organs and limits plastic. Considering the low incidence of gastric cancer in Western countries, the issues regarding LAG will hardly be addressed by RCTs. Therefore, we believe that, as long as basic surgical principles are followed, it is reasonable to expect similar oncologic long-term results with the open and the laparoscopic approaches. Notwithstanding the flaws previously addressed, our study reports no difference in morbidity and quality of the oncological specimen between LAG and OG for gastric adenocarcinoma. Laparoscopic assisted gastrectomy is a technically safe and feasible procedure in experienced hands. It satisfies the oncologic requirement by offering the same radical resection as the open approach in terms of negative margins and adequate LN retrieval. Longer follow-up in prospective trials is warranted to definitely conclude on survival outcomes in the Western setting. In the meantime, the use of LAG in experienced laparoscopic centres appears justified in a selected population.

**Competing interests:** None declared.

**Contributors:** J. Hallet and J.-P. Gagné designed the study and wrote the article. J. Hallet, S. Labidi and A. Clairoux acquired the data, which J. Hallet, A. Bouchard-Fortier and J.-P. Gagné analyzed. All authors reviewed the article and approved its publication.

**References**